|Bid||0.00 x 3000|
|Ask||0.00 x 2200|
|Day's Range||37.06 - 37.45|
|52 Week Range||27.88 - 40.97|
|Beta (5Y Monthly)||0.66|
|PE Ratio (TTM)||14.68|
|Earnings Date||Oct 27, 2020|
|Forward Dividend & Yield||1.52 (4.05%)|
|Ex-Dividend Date||Nov 05, 2020|
|1y Target Est||41.33|
As new cases in the United States average at around 59,000 a day with the most recent surge, AstraZeneca is reportedly going to re-start its vaccine trials in the U.S. according to Reuters and Eli Lilly is bringing in an outside advisor to oversee the issues with its New Jersey plant. Yahoo Finance’s Anjalee Khemlani joins The Final Round to discuss the latest on the coronavirus.
The leaders of key U.S. health agencies said in a media briefing Wednesday they are optimistic one or two Covid-19 vaccines will be approved and begin distribution later this year.
The United States is likely to have enough safe and effective COVID-19 vaccines available to inoculate the most vulnerable Americans by the end of 2020, Health and Human Services Secretary Alex Azar said on Wednesday. The U.S. government is "cautiously optimistic" that one or two vaccines, likely from Pfizer Inc or Moderna Inc , will be available by the end of the year and can begin to be distributed to Americans, officials said during a news conference. Azar said he expects all seniors, healthcare workers, and first responders will be able to receive a vaccine as soon as January, with the rest of the American public able to get a vaccine by April.